• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Jan De Witte joins GHO Capital as Operating Partner

    2/11/25 4:30:00 AM ET
    $IART
    $RMD
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $IART alert in real time by email

    Jan De Witte joins GHO Capital as Operating Partner

    Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio

    London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner.

    Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integra", NASDAQ:IART), a global leader in regenerative tissue technologies, and neurosurgical and ENT solutions. At Integra Jan drove international expansion and operational excellence, and through strategic acquisitions and innovation added $1 billion to the total addressable market of the company's offerings.

    Prior to Integra, Jan served as CEO of Barco N.V. (EBR: BAR), directing the advanced visualisation technology company's digital transformation and global market expansion. He strengthened Barco's position in the healthcare, entertainment, and enterprise sectors through new product launches and operational improvements and global market expansions. Earlier in his career, he spent 18 years at GE Healthcare leading global teams in Digital Health, Services, Manufacturing, Quality and Supply Chain across the Americas, EMEA, and Asia. Jan's career started with foundational roles in Operations at Procter & Gamble and as Senior Consultant at McKinsey in Europe.

    Jan currently serves as a Director of ResMed Inc. (NYSE:RMD), a digital health and medical device leader. His board experience includes previous roles at Barco N.V. and international joint ventures. He holds an M.B.A. from Harvard Business School and Master's and Bachelor's degrees in electromechanical engineering with highest distinction from KU Leuven, Belgium.

    As Operating Partner, Jan will leverage his extensive leadership experience and global network to support and grow GHO's portfolio companies, as well as supporting with the firm's transatlantic deal origination.

    The Partners at GHO Capital commented: "Jan brings a wealth of healthcare industry expertise and a strong track record to our team as we look to implement our proven operational playbook and drive expansion and growth across our portfolio. The healthcare sector is experiencing significant innovation, supported by favourable market conditions, and Jan's experience will help us identify businesses with the most substantial growth potential. On behalf of the entire GHO team, we warmly welcome him and look forward to the positive impact he will make."

    Commenting on his new appointment, Jan De Witte, Operating Partner at GHO Capital, said: "My focus throughout my career has always been to support innovative healthcare companies as they grow and transform, whilst creating long-term investor value. I am excited to be joining GHO Capital, one of Europe's leading healthcare specialist private equity firms, who are committed to driving the highest standards across the healthcare sector. I look forward to working with the team and leveraging my expertise to support GHO's portfolio companies realise their full potential."

    -Ends-

    Further information:

    GHO Capital Partners LLP

    T +44 20 3700 7440

    E [email protected]

    For Media Enquiries



    ICR Healthcare



    Amber Fennell, Angela Gray, Kris Lam











    Tel: +44 (0) 20 3709 5700



    [email protected]







    About GHO Capital

    Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. GHO Capital applies global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market leading businesses of strategic global value. GHO Capital's proven investment track record reflects the unrivalled depth of our industry expertise and network. GHO Capital partners with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit www.ghocapital.com.



    Primary Logo

    Get the next $IART alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IART
    $RMD

    CompanyDatePrice TargetRatingAnalyst
    ResMed Inc.
    $RMD
    7/16/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    ResMed Inc.
    $RMD
    7/15/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    Integra LifeSciences Holdings Corporation
    $IART
    3/31/2025Hold → Buy
    Argus
    ResMed Inc.
    $RMD
    3/19/2025$280.00Overweight
    Morgan Stanley
    ResMed Inc.
    $RMD
    3/19/2025Overweight
    Morgan Stanley
    ResMed Inc.
    $RMD
    1/16/2025Buy
    Goldman
    ResMed Inc.
    $RMD
    1/10/2025$252.00Neutral
    Piper Sandler
    ResMed Inc.
    $RMD
    12/13/2024$250.00Hold
    Stifel
    More analyst ratings

    $IART
    $RMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Essig Stuart bought $1,499,979 worth of shares (52,641 units at $28.49), increasing direct ownership by 12% to 487,922 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    5/24/24 4:08:19 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Hill Barbara B bought $995,816 worth of shares (36,350 units at $27.40) (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    5/22/24 4:09:18 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    $RMD
    SEC Filings

    View All

    SEC Form 8-K filed by ResMed Inc.

    8-K - RESMED INC (0000943819) (Filer)

    8/18/25 4:20:28 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by ResMed Inc.

    10-K - RESMED INC (0000943819) (Filer)

    8/7/25 8:44:48 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Integra LifeSciences Holdings Corporation

    SCHEDULE 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

    8/5/25 11:50:40 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    $RMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Product Officer Leong Justin was granted 5,462 units of ReMed Common Stock, increasing direct ownership by 25% to 27,180 units (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    8/19/25 3:29:06 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Sandercock Brett was granted 5,462 units of ResMed Common Stock, increasing direct ownership by 7% to 88,745 units (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    8/19/25 2:50:03 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Farrell Michael J. was granted 12,289 units of ResMed Common Stock, increasing direct ownership by 3% to 467,792 units (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    8/19/25 2:28:50 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $IART
    $RMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ResMed upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded ResMed from Sector Perform to Outperform and set a new price target of $294.00

    7/16/25 7:50:57 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    ResMed upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded ResMed from Sector Perform to Outperform and set a new price target of $294.00

    7/15/25 8:29:55 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Integra upgraded by Argus

    Argus upgraded Integra from Hold to Buy

    3/31/25 8:28:08 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    $RMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs

    SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced that its AirTouch™ N30i nasal cradle mask won two prestigious Red Dot Awards: Product Design 2025 in both the Innovative Products and Medical Design & Healthcare categories. The AirTouch N30i features Resmed's first-ever nasal cushion made from fabric fused with silicone, designed to deliver both clinical performance and a therapy experience that feels more natural and comfortable making it easier for people to start and stick with CPAP therapy. Launched in October 2024, the AirTouch N30i builds on

    8/21/25 9:00:00 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio

    Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics Operations Her appointment brings over 30 years of strategic, commercial, and operational expertise in the pharmaceutical and broader healthcare industry, with a focus on digital innovation SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company also announced that board member Rich Sulpizio is thanked for two decades of contributions to Resmed, and will retire from the board, not standing for reelection at the 2025 Annual Meeting of Stockholders, scheduled fo

    8/18/25 4:15:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    REPAY Appoints New Chief Financial Officer

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    Real Estate
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $IART
    $RMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Integra LifeSciences Holdings Corporation

    SC 13G - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

    11/12/24 5:20:30 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

    SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

    11/12/24 12:54:20 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

    SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

    8/12/24 10:06:35 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    $RMD
    Financials

    Live finance-specific insights

    View All

    Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025

    Year-over-year revenue grows 10%, operating profit up 19%, non-GAAP operating profit up 19%Operating cash flow of $539 millionQuarterly dividend increases 13% to $0.60 per share Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended June 30, 2025. Fourth Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 10% to $1.3 billion; up 9% on a constant currency basis Gross margin improved 230 bps to 60.8%; non-GAAP gross margin improved 230 bps to 61.4

    7/31/25 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Integra LifeSciences Reports Second Quarter 2025 Financial Results

    PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2025. Second Quarter 2025 Highlights Second quarter revenues exceeded guidance; adjusted earnings per diluted share (EPS) at the top end of the rangeSecond quarter revenues of $415.6 million decreased (0.6)% on a reported basis and (1.4)% on an organic basis compared to the prior year.Second quarter GAAP earnings per diluted share of $(6.31), compared to $(0.16) in the prior year primarily reflecting a goodwill impairment charge of $511 million, recorded during t

    7/31/25 6:00:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Integra LifeSciences to Host Second Quarter 2025 Financial Results Conference Call on July 31, 2025

    PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release second quarter 2025 financial results on Thursday, July 31, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the

    7/14/25 4:35:00 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    $RMD
    Leadership Updates

    Live Leadership Updates

    View All

    REPAY Appoints New Chief Financial Officer

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    Real Estate
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Resmed Names Salli Schwartz as Chief Investor Relations Officer

    SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she

    4/21/25 5:00:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Jan De Witte joins GHO Capital as Operating Partner

    Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

    2/11/25 4:30:00 AM ET
    $IART
    $RMD
    Medical/Dental Instruments
    Health Care